Mechanisms and future directions for angiogenesis-based cancer therapies

Journal of Clinical Oncology

Volumn 20, Issue 18, 2002, Pages 3906-3927

  Scappaticci, Frank A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; AE 941; ALPHA2A INTERFERON; ANGIOSTATIN; ANGIOZYME; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANCER VACCINE; CELECOXIB; CETUXIMAB; CILENGITIDE; ENDOSTATIN; GEFITINIB; IM 862; IMC 1C11; INTEGRIN; INTERLEUKIN 12; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; RADIOLIGAND; REBIMASTAT; RECEPTOR ANTIBODY; SQUALAMINE; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ANGIOGENESIS; CANCER DIAGNOSIS; CANCER RESISTANCE; CANCER THERAPY; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; GENE THERAPY; GENETIC ANALYSIS; HUMAN; IMAGING; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; RADIOIMMUNOTHERAPY; REVIEW; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; ENDOTHELIUM, VASCULAR; FORECASTING; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0037106374     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.01.033     Document Type: Review

References (231)

1. Angiogenesis in cancer, vascular, rheumatoid and other disease
2. Antiangiogenic therapy
3. Mechanisms of drug resistance
4. A cancer therapy resistant to resistance
5. Endothelial cells of tumor vessels: Abnormal but not absent
6. Genes expressed in human tumor endothelium
7. Regulation of tumor angiogenesis by organ-specific cytokines
8. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis
9. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
10. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies
11. Tumour vasculature as a target for anticancer therapy
12. Signaling vascular morphogenesis and maintenance
13. Mechanisms of angiogenesis
14. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
15. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
16. Maintenance of vascular integrity in the embryo requires signaling through the fibroblast growth factor receptor
17. Failure of bloodisland formation and vasculogenesis in Flk-1-deficient mice
18. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
19. Implementation of intussusceptive microvascular growth in the chicken chorioallantoic membrane (CAM): 1. Pillar formation by folding of the capillary wall
20. Relationship between vasculogenesis, angiogenesis and haemopoiesis during avian ontogeny
21. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
22. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells
23. Flk-1, an flt-related receptor tyrosine kinase is an early marker for endothelial cell precursors
24. Oxygen and the growth and development of retinal vessels: In vivo and in vitro studies. The XX Francis I. Proctor Lecture
25. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
26. Vascular-specific growth factors and blood vessel formation
27. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
28. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
29. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
30. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis
31. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis
32. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis
33. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B 4
34. Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis
35. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development
36. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
37. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma
38. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
39. Suppression of tumor growth through disruption of hypoxia-inducible transcription
40. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1
41. Isolation of putative progenitor endothelial cells for angiogenesis
42. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
43. A role for hematopoietic stem cells in promoting angiogenesis
44. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors
45. A common precursor for hematopoietic and endothelial cells
46. Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model
47. Genetically modified CD34+ cells exert a cytotoxic bystander effect on human endothelial and cancer cells
48. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
49. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts
50. Can mosaic tumor vessels facilitate molecular diagnosis of cancer?
51. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
52. Increased bone marrow vascularization in patients with acute myeloid leukaemia: A possible role for vascular endothelial growth factor
53. Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL)
54. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias
55. The growth of highly proliferative acute lymphoblastic leukemia may be independent of stroma and/or angiogenesis
56. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice
57. Novel therapeutic agents for the treatment of myelodysplastic syndromes
58. Stable remission after administration of the receptor tyrosine kinase inhibitor SU 5416 in a patient with refractory acute myeloid leukemia
59. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry
60. Vasculogenic mimicry and tumor angiogenesis
61. Molecular biology of breast cancer metastasis: Molecular expression of vascular markers by aggressive breast cancer cells
62. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: Role in vasculogenic mimicry
63. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma
64. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors
65. Molecular profiling of human cancer
66. Clinical trials of antiangiogenic drugs: Opportunities, problems, and assessment of initial results
67. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
68. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
69. The microenvironment of the tumour-host interface
70. Dominant effector genetics in mammalian cells
71. Organ targeting in vivo using phage display peptide libraries
72. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
73. Targeting tumor vasculature with homing peptides from phage display
74. Requirement of vascular integrin alpha v beta 3 for angiogenesis
75. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis
76. Steps toward mapping the human vasculature by phage display
77. Redefining the target: Chemotherapeutics as antiangiogenics
78. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
79. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications
80. Extracellular matrix inhibits apoptosis and enhances endothelial cell differentiation by a NfkappaB-dependent mechanism
81. Selective modulation of collagenase 1 gene expression by the chemotherapeutic agent doxorubicin
82. Antiangiogenesis is produced by nontoxic doses of vinblastine
83. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
84. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
85. Continuous low-dose anti-angiogenic/metronomic chemotherapy: From the research laboratory into the oncology clinic
86. Dose-dense therapy with paclitaxel via weekly 1-hour infusion: Preliminary experience in the treatment of metastatic breast cancer
87. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
88. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors
89. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis
90. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
91. Establishing a link between oncogenes and tumor angiogenesis
92. Thalidomide is an inhibitor of angiogenesis
93. Current role of thalidomide in cancer treatment
94. Activity of thalidomide in AIDS-related Kaposi's sarcoma
95. Antitumor activity of thalidomide in refractory multiple myeloma
96. Thalidomide in the treatment of cancer
97. Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
98. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
99. Nonsteroidal anti-inflammatory drugs and colorectal cancer: Evolving concepts of their chemopreventive actions
100. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs)
101. Aspirin for cancer
102. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
103. PGH synthase isoenzyme selectivity: The potential for safer nonsteroidal antiinflammatory drugs
104. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis
105. Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth
106. The hemostatic system as a regulator of angiogenesis
107. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
108. The presence and release of alpha 2-antiplasmin from human platelets
109. The role of the pericellular fibrinolytic system in angiogenesis
110. Platelet alpha2-macroglobulin and alpha1-antitrypsin
111. Mechanism of action of angiostatic steroids: Suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis
112. Kringle domains of human angiostatin: Characterization of the anti-proliferative activity on endothelial cells
113. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9)
114. Tumors: Wounds that do not heal-Similarities between tumor stroma generation and wound healing
115. Angiogenesis: A dynamic balance of stimulators and inhibitors
116. Antiangiogenic gene therapy
117. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie 2
118. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
119. Gene therapy strategies for tumor antiangiogenesis
120. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA
121. Retroviral vectorproducer cell mediated angiogenesis inhibition restricts neuroblastoma growth in vivo
122. Inhibition of matrix metalloproteinases by over-expression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas
123. Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors
124. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2
125. Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo
126. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer
127. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and il-12: A role for combined anti-angiogenesis and immonotherapy
128. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy
129. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice
130. Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer
131. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy
132. Local endostatin treatment of gliomas administered by microencapsulated producer cells
133. Intramuscular electroporation delivery of IFN-alpha gene therapy for inhibition of tumor growth located at a distant site
134. Anti-angiogenic treatment strategies for malignant brain tumors
135. In situ retroviralmediated gene transfer for the treatment of brain tumors in rats
136. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
137. A high-affinity human antibody that targets tumoral blood vessels
138. Radiolabeled alpha(v)beta3 integrin antagonists: A new class of tracers for tumor targeting
139. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging
140. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy
141. Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi
142. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin
143. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using 125I-labeled anti-endoglin monoclonal antibodies
144. Monoclonal antibody therapy of cancer
145. Transport of molecules in the tumor interstitium: A review
146. Dual origin of intimal cells in cardiac-allograft arteriosclerosis
147. Immunochemical identification of human endothelial cells on the lining of a ventricular assist device
148. The role of circulating cells in the healing of vascular prostheses
149. Proof of fallout endothelialization of impervious Dacron grafts in the aorta and inferior vena cava of the dog
150. Characterization of hematopoietic cells arising on the textured surface of left ventricular assist devices
151. Angiogenesis-directed implantation of genetically modified endothelial cells in mice
152. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data
153. Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignangies
154. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine
155. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development
156. Matrix metalloproteinases in tumor invasion and metastasis
157. Development of matrix metalloproteinase inhibitors in cancer therapy
158. Matrix metalloproteinases and metastasis
159. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
160. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system
161. Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors
162. Matrix metalloproteinase inhibitors: Present achievements and future prospects
163. Matrix metalloproteinase inhibitors
164. Matrix metalloproteinase inhibitors
165. Clinical studies with matrix metalloproteinase inhibitors
166. Broad antitumor and antiangiogenic activities of AG 3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
167. AE 941-neovastat
168. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials
169. New molecular targets and biological therapies in sarcomas
170. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies
171. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin
172. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer
173. Preclinical and clinical studies of MMP inhibitors in cancer
174. Membrane protein secretases
175. Promising new developments in cancer chemotherapy
176. HL-60 leukemia cells produce an autocatalytically truncated form of matrix metalloproteinase-9 with impaired sensitivity to inhibition by tissue inhibitors of metalloproteinases
177. Induction of stromal uPA during Batimastat therapy of human breast tumor xenografts
178. Combined effects of angiostatin and ionizing radiation in antitumour therapy
179. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
180. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth
181. Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities
182. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation
183. Statin-AE: A novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity
184. Tyrosine kinase inhibitors-ZD1839 (Iressa)
185. Epidermal growth factor receptor biology (IMC-C225)
186. Angiogenesis and antiangiogenic approaches to sarcomas
187. SU 6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
188. New paradigms for the treatment of cancer: The role of anti-angiogenesis agents
189. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
190. Angiozyme: A novel angiogenesis inhibitor
191. Pilot study of vitaxin, an angiogenesis inhibitor, in patients with advanced leiomyosarcomas
192. Cell surface glypicans are low-affinity endostatin receptors
193. Endostatin binds tropomyosin: A potential modulator of the antitumor activity of endostatin
194. Interaction of endostatin with integrins implicated in angiogenesis
195. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase
196. Angiostatin binds ATP synthase on the surface of human endothelial cells
197. Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation
198. Specific Interaction of angiostatin with integrin alpha vbeta 3 in endothelial cells
199. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth
200. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers
201. Angiogenesis inhibitors in the treatment of lung cancer
202. IL-12-induced production of IL-10 and interferon-gamma by mononuclear cells in lung cancer-associated malignant pleural effusions
203. Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: Toxicity, bioavailability and the effect of food
204. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
205. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: A phase I AIDS malignancy consortium study
206. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma
207. Angiostatin induces and sustains dormancy of human primary tumors in mice
208. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
209. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model
210. Antiangiogenesis agents
211. Clinical implications of circulating angiogenic factors in cancer patients
212. Endothelial progenitor cells as putative targets for angiostatin
213. Tumor angiogenesis: Molecular pathology, therapeutic targeting, and imaging
214. First pass FDG measured blood flow in tumors: A comparison with O-15 labeled water measured blood flow
215. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU 5416 in patients with solid tumors
216. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
217. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice
218. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin
219. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, plateletderived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
220. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing
221. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing
222. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer
223. A randomized phase II trial comparing rhumAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with Stage IIIb/IV NSCLC
224. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: Time to take stock!
225. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
226. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells
227. Control of apoptosis during angiogenesis by survivin expression in endothelial cells
228. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting
229. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
230. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras
231. Effect of p 53 status on tumor response to antiangiogenic therapy